January 27, 2020

• January 27, 2020

                                                                                                                                 

• January 27, 2020
• “We have a vital mission to protect and promote public health and the FDA is closely collaborating with our domestic and international public health partners to mitigate the impact of the novel coronavirus that emerged in Wuhan, China,” said FDA Commissioner Stephen M. Hahn, M.D. “We are actively leveraging the vast breadth of the FDA’s expertise and have begun employing the full range of our public health authorities to facilitate the development and availability of investigational medical products to help address this urgent public health situation.”
• January 27, 2020: FDA requests that diagnostic test sponsors interested in potential Emergency Use Authorization (EUA) for tests to detect 2019-nCoV contact CDRH-EUA-Templates@fda.hhs.gv for further information and templates. Also see: How to Submit a Pre-EUA for In vitro Diagnostics to FDA

                                                                  

Crona Viras

                                      Crona Viras  in China                                                           

        

The China Coronaviruses is formally called “novel coronavirus (2020nCoV)”, which is in the same family of infections as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).

at a news conference in Beijing said the virus can be passed from person to person, but animals are usually the origin of coronaviruses. The infection is thought to have originated in a seafood market which also sold illegal wildlife meat in Wuhan, which now have been closed and sealed off by local government to limit potential spread.